FDLI CEO has device background
Executive Summary
Food & Drug Law Institute names former Carl Zeiss CEO James Kelly president and CEO effective Aug. 14. Prior to working at Zeiss, Kelly held various positions with Siemens Medical, including head of human resources. Kelly's device background contrasts with his predecessor Jerome Halperin, who headed U.S. Pharmacopeia prior to joining FDLI nearly five years ago (1"The Pink Sheet" April 2, 2001, p. 36)...
You may also be interested in...
FDLI
Former U.S. Pharmacopeia CEO Jerome Halperin will replace John Villforth as president of the Food & Drug Law Institute July 1. Halperin serves as FDLI treasurer and has been a member of the board of directors since 1991. Prior to his tenure at USP from 1990 to 2000, Halperin worked six years as VP-technology for CIBA Consumer Pharmaceuticals. He previously served as FDA Office of Drugs Acting Director
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.